Celsense

 

 

NEWS RELEASE - For Immediate Release

Celsense to Present Use of in vivo Cellular Imaging Technology with Human at International Cell Therapy Conference

Non-invasive, in vivo visualization and tracking of Cell Sense labeled cells demonstrates potential clinical utility of 19F MRI imaging in cellular therapy

Pittsburgh, PA (April 30, 2009) —Celsense, Inc. announced today that one of its Research Scientists, Brooke M. Helfer, Ph.D., will present cellular imaging data from its lead compound (Cell Sense) at the ISCT (International Society for Cellular Therapy) conference to be held May 3-6, 2009, in San Diego, CA. 

The study demonstrated that human immature and mature dendritic cells (DCs) were clearly capable of being detected by 19F MRI. Moreover, using this technology, the in vivo imaging assay demonstrated the superior lymph node homing capacity of the 19F labeled mature DCs compared to immature DCs, thus demonstrating the effectiveness of this tracking method and the capacity of mature DCs to maintain in vivo migratory functionality. 

Labeled human dendritic cells were visualized in vivo and their migration tracked after injection using 19F MRI. Following either subcutaneous or intramuscular injection into the quadriceps of NOD-SCID mice, human immature and mature dendritic cells were clearly capable of being detected by 19F MRI. The non-invasive visual specificity of 19F labeled cells provided by MRI demonstrates a potential clinical application of 19F in cellular therapy. 

Cell therapy is one field of research aiming to target and destroy cancer cells. A current limitation of cell therapy is the inability to track the movement of these cells once they are administered to a patient. By facilitating non-invasive visual specificity of 19F labeled cells provided by MRI, the Cell Sense technology may prove to be a useful clinical tool in the application of cell therapy in the treatment of cancer. 

About Cell Sense—Cell Sense is a fluorocarbon tracer agent used to label cells in vitro then transplanted thus enabling investigators and clinicians to non-invasively track the administration and delivery of therapeutic and diagnostic cells in vivo using MRI.  Applications include tracking therapeutic cells in regenerative medicine and immunotherapy applications, and observing localized immune system response by tracking populations of immune system cells.  Using software developed by Celsense, the investigators can quantify the number of labeled cells in a user-specified region of interest.

About Celsense, Inc.—Celsense, Inc. (the “Company” and “Celsense”) is an emerging biotechnology company offering novel pre-clinical and clinical-grade molecular imaging agents used to non-invasively visualize and measure biological processes at the cellular level in living systems. The core innovations of the Company involve molecular imaging agents that can be used to observe the trafficking of cells in small or large animals including humans using magnetic resonance techniques. The mission of the Company is to establish Celsense as the standard for cellular and molecular imaging in human health research and therapeutics.

Contact Information:

Charlie O’Hanlon, President and CEO
Celsense, Inc.
(412) 263-2870
charlie@celsense.com